Gujarat Kidney and Super Speciality Limited has received regulatory fines from both major Indian stock exchanges for non-compliance with SEBI listing regulations. The healthcare company disclosed the penalties in a regulatory filing dated April 16, 2026, addressing violations related to board meeting intimation requirements.

Regulatory Penalties Imposed

Both BSE Limited and National Stock Exchange of India Limited imposed identical fines on the company for regulatory non-compliance. The penalties were communicated to the company on April 15, 2026, through official email notifications from both exchanges.

Nature of Violation

The fines were imposed for the company's failure to furnish prior intimation about board of directors meetings as mandated under Regulation 29(2)/29(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation requires listed companies to provide advance notice to stock exchanges before conducting board meetings.

Company's Response and Impact Assessment

Gujarat Kidney and Super Speciality Limited has committed to making payment of both fines within the timelines prescribed by the respective stock exchanges. The company's management, led by Managing Director Pragnesh Bharpoda, has assessed the impact of these penalties on business operations.

Regulatory Compliance Framework

The disclosure was made pursuant to Regulation 30 of SEBI Listing Regulations, 2015, which requires companies to inform exchanges about material events and regulatory actions. The company provided detailed information about the violations and penalties in Annexure-A format as prescribed by SEBI circulars.

The regulatory filing was digitally signed by Managing Director Pragnesh Bharpoda (DIN: 01033141) and submitted to both exchanges' listing departments. The company operates from its registered office in Vadodara, Gujarat, and is engaged in healthcare and super specialty medical services.

Gujarat Kidney and Super Speciality Limited has fulfilled its regulatory obligations by submitting the mandatory certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The healthcare company notified both major stock exchanges about this compliance requirement on April 7, 2026.

Regulatory Compliance Details

The certificate was issued by MUFG Intime India Private Limited (formerly Link Intime India Private Limited), which serves as the company's registrar and share transfer agent. The certification, dated April 6, 2026, was submitted in compliance with Regulation 74(5) of SEBI regulations.

Share Holding Status Confirmation

The certificate confirms that all shares of Gujarat Kidney and Super Speciality Limited have been issued in electronic form during the quarter ended March 31, 2026. The registrar specifically stated that there is no holding in physical form for this period.

Exchange Notifications

The company has formally notified both BSE Limited and National Stock Exchange of India Limited about the certificate submission. The notification was signed by Pragnesh Yashwantsinh Bharpoda, Managing Director, who requested the exchanges to update their records and disseminate the information on their websites.

Depositories Information

Copies of the certificate were also sent to both major depositories in India:

• National Securities Depository Limited (NSDL) at Trade World, Lower Parel, Mumbai
• Central Depositories Services (India) Limited (CDSL) at Marathone Futurex, Lower Parel, Mumbai

This submission represents the company's ongoing commitment to maintaining transparency and regulatory compliance in its operations as a publicly listed healthcare entity.